262 Relating to: reporting by treatment programs using methadone and requiring review of prescription drug monitoring database.

  Date of enactment: March 17, 2016
2015 Assembly Bill 367   Date of publication*: March 18, 2016

* Section 991.11, Wisconsin Statutes : Effective date of acts. "Every act and every portion of an act enacted by the legislature over the governor's partial veto which does not expressly prescribe the time when it takes effect shall take effect on the day after its date of publication."

2015 WISCONSIN ACT 262

An Act to create 51.4223 of the statutes; relating to: reporting by treatment programs using methadone.

The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:

Section 1 . 51.4223 of the statutes is created to read:

51.4223 Reporting by methadone treatment programs. (1) Annually, a treatment program that treats addiction using methadone shall report to the department all of the following:

(a) The ratio of treatment program staff to the number of individuals receiving methadone treatment.

(b) The number of individuals receiving methadone treatment who are receiving behavioral health services.

(c) The relapse rate or the average time an individual is receiving methadone treatment.

(d) The treatment program's plan for tapering individuals off of methadone.

(e) The average mileage that individuals receiving treatment in the methadone treatment program are traveling to receive treatment at the facility.

(f) The number of doses of methadone that individuals carry out of the facility to take outside of treatment program staff supervision.

(g) The number of individuals in the treatment program on each of the 3 forms of medication-assisted treatment, specifically methadone, buprenorphene-containing products, and oral or extended-release injectable naltrexone, that are approved by the federal food and drug administration.

(h) The number of individuals who engage in a program of aftercare and the number of individuals who are treated with antagonist medication, such as oral or extended-release injectable naltrexone, as part of relapse prevention.

(i) Any other information specified by the department.

(2) The treatment program shall ensure that the information under sub. (1) is provided in a manner that does not permit the identification of an individual who is receiving methadone treatment from the program.